Mirador Therapeutics, Inc.

This early-stage study tested the safety of a new drug called MT-701 in 46 healthy adults aged 19 to 55. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. The goal was not to treat any disease, …

This early-phase trial tested the safety and tolerability of a new drug called MT-501 in 72 healthy adults aged 19 to 55. Participants received either single or multiple oral doses of MT-501 or a placebo. The main goal was to monitor for side effects and how the drug moves throug…